• Je něco špatně v tomto záznamu ?

Structure-Activity Relationship Study of Dexrazoxane Analogues Reveals ICRF-193 as the Most Potent Bisdioxopiperazine against Anthracycline Toxicity to Cardiomyocytes Due to Its Strong Topoisomerase IIβ Interactions

A. Jirkovská, G. Karabanovich, J. Kubeš, V. Skalická, I. Melnikova, J. Korábečný, T. Kučera, E. Jirkovský, L. Nováková, H. Bavlovič Piskáčková, J. Škoda, M. Štěrba, CA. Austin, T. Šimůnek, J. Roh

. 2021 ; 64 (7) : 3997-4019. [pub] 20210322

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21018854

Cardioprotective activity of dexrazoxane (ICRF-187), the only clinically approved drug against anthracycline-induced cardiotoxicity, has traditionally been attributed to its iron-chelating metabolite. However, recent experimental evidence suggested that the inhibition and/or depletion of topoisomerase IIβ (TOP2B) by dexrazoxane could be cardioprotective. Hence, we evaluated a series of dexrazoxane analogues and found that their cardioprotective activity strongly correlated with their interaction with TOP2B in cardiomyocytes, but was independent of their iron chelation ability. Very tight structure-activity relationships were demonstrated on stereoisomeric forms of 4,4'-(butane-2,3-diyl)bis(piperazine-2,6-dione). In contrast to its rac-form 12, meso-derivative 11 (ICRF-193) showed a favorable binding mode to topoisomerase II in silico, inhibited and depleted TOP2B in cardiomyocytes more efficiently than dexrazoxane, and showed the highest cardioprotective efficiency. Importantly, the observed ICRF-193 cardioprotection did not interfere with the antiproliferative activity of anthracycline. Hence, this study identifies ICRF-193 as the new lead compound in the development of efficient cardioprotective agents.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21018854
003      
CZ-PrNML
005      
20210830100433.0
007      
ta
008      
210728s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1021/acs.jmedchem.0c02157 $2 doi
035    __
$a (PubMed)33750129
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Jirkovská, Anna $u Faculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, 50005 Hradec Králové, Czech Republic
245    10
$a Structure-Activity Relationship Study of Dexrazoxane Analogues Reveals ICRF-193 as the Most Potent Bisdioxopiperazine against Anthracycline Toxicity to Cardiomyocytes Due to Its Strong Topoisomerase IIβ Interactions / $c A. Jirkovská, G. Karabanovich, J. Kubeš, V. Skalická, I. Melnikova, J. Korábečný, T. Kučera, E. Jirkovský, L. Nováková, H. Bavlovič Piskáčková, J. Škoda, M. Štěrba, CA. Austin, T. Šimůnek, J. Roh
520    9_
$a Cardioprotective activity of dexrazoxane (ICRF-187), the only clinically approved drug against anthracycline-induced cardiotoxicity, has traditionally been attributed to its iron-chelating metabolite. However, recent experimental evidence suggested that the inhibition and/or depletion of topoisomerase IIβ (TOP2B) by dexrazoxane could be cardioprotective. Hence, we evaluated a series of dexrazoxane analogues and found that their cardioprotective activity strongly correlated with their interaction with TOP2B in cardiomyocytes, but was independent of their iron chelation ability. Very tight structure-activity relationships were demonstrated on stereoisomeric forms of 4,4'-(butane-2,3-diyl)bis(piperazine-2,6-dione). In contrast to its rac-form 12, meso-derivative 11 (ICRF-193) showed a favorable binding mode to topoisomerase II in silico, inhibited and depleted TOP2B in cardiomyocytes more efficiently than dexrazoxane, and showed the highest cardioprotective efficiency. Importantly, the observed ICRF-193 cardioprotection did not interfere with the antiproliferative activity of anthracycline. Hence, this study identifies ICRF-193 as the new lead compound in the development of efficient cardioprotective agents.
650    _2
$a zvířata $7 D000818
650    _2
$a novorozená zvířata $7 D000831
650    _2
$a kardiotonika $x chemická syntéza $x metabolismus $x terapeutické užití $7 D002316
650    _2
$a kardiotoxicita $x farmakoterapie $7 D066126
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a proliferace buněk $x účinky léků $7 D049109
650    _2
$a DNA-topoisomerasy typu II $x metabolismus $7 D004250
650    _2
$a daunomycin $x toxicita $7 D003630
650    _2
$a lidé $7 D006801
650    _2
$a simulace molekulového dockingu $7 D062105
650    _2
$a simulace molekulární dynamiky $7 D056004
650    _2
$a molekulární struktura $7 D015394
650    _2
$a kardiomyocyty $x účinky léků $7 D032383
650    _2
$a piperaziny $x chemická syntéza $x metabolismus $x terapeutické užití $7 D010879
650    _2
$a vazba proteinů $7 D011485
650    _2
$a potkani Wistar $7 D017208
650    _2
$a Saccharomyces cerevisiae $x chemie $7 D012441
650    _2
$a Saccharomyces cerevisiae - proteiny $x metabolismus $7 D029701
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
650    _2
$a inhibitory topoisomerasy II $x chemická syntéza $x metabolismus $x terapeutické užití $7 D059005
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Karabanovich, Galina $u Faculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, 50005 Hradec Králové, Czech Republic
700    1_
$a Kubeš, Jan $u Faculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, 50005 Hradec Králové, Czech Republic
700    1_
$a Skalická, Veronika $u Faculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, 50005 Hradec Králové, Czech Republic
700    1_
$a Melnikova, Iuliia $u Faculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, 50005 Hradec Králové, Czech Republic
700    1_
$a Korábečný, Jan $u Biomedical Research Center, University Hospital Hradec Kralove, Sokolska 581, 50005 Hradec Králové, Czech Republic $u Faculty of Military Health Sciences, University of Defence, Třebešská 1575, 50005 Hradec Králové, Czech Republic
700    1_
$a Kučera, Tomáš $u Faculty of Military Health Sciences, University of Defence, Třebešská 1575, 50005 Hradec Králové, Czech Republic
700    1_
$a Jirkovský, Eduard $u Faculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, 50005 Hradec Králové, Czech Republic
700    1_
$a Nováková, Lucie $u Faculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, 50005 Hradec Králové, Czech Republic
700    1_
$a Bavlovič Piskáčková, Hana $u Faculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, 50005 Hradec Králové, Czech Republic
700    1_
$a Škoda, Josef $u Faculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, 50005 Hradec Králové, Czech Republic
700    1_
$a Štěrba, Martin $u Department of Pharmacology, Faculty of Medicine in Hradec Králové, Charles University, Šimkova 870, 50003 Hradec Králové, Czech Republic
700    1_
$a Austin, Caroline A $u Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne NE2 4HH, United Kingdom
700    1_
$a Šimůnek, Tomáš $u Faculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, 50005 Hradec Králové, Czech Republic
700    1_
$a Roh, Jaroslav $u Faculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, 50005 Hradec Králové, Czech Republic
773    0_
$w MED00010049 $t Journal of medicinal chemistry $x 1520-4804 $g Roč. 64, č. 7 (2021), s. 3997-4019
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33750129 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830100433 $b ABA008
999    __
$a ok $b bmc $g 1689824 $s 1139300
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 64 $c 7 $d 3997-4019 $e 20210322 $i 1520-4804 $m Journal of medicinal chemistry $n J Med Chem $x MED00010049
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Možnosti archivace